摘要
根治性膀胱切除加盆腔区域淋巴结清扫是治疗浸润性膀胱癌的标准术式,但对于非器官局限性膀胱癌,局部复发与远处转移的风险较高。对这部分患者进行以顺铂为基础的新辅助化疗,可以降低复发率,改善手术疗效,提高生存率。对新辅助化疗敏感的患者,可以考虑保留膀胱的保守治疗。
出处
《临床泌尿外科杂志》
2007年第7期554-557,共4页
Journal of Clinical Urology
参考文献16
-
1Stein J P, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: longterm results in 1,054 patients [J].J Clin Oncol, 2001, 19(3): 666-675.
-
2Herr HW. Superiority of ratio based lymph node staging for bladder cancer[J]. J Urol, 2003,169 (3) : 943-945.
-
3Kassouf W, Leibovici D, Munsell M F, et al. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy [J].J Urol, 2006,176(1):53--57.
-
4Sternberg C N, de Mulder P H, Schornagel J H, et al. Randomized phase Ⅲ trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924[J]. J Clin Oncol, 2001,19(10) :2638-2646.
-
5vonder Maase H, Hansen S W, Roberts J T, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase Ⅲ study[J]. J Clin Oncol,2000,18(17) :3068--3077.
-
6Sonpavde G, Petrylak D P. Perioperative chemotherapy for bladder cancer[J]. Crit Rev Oncol Hemato, 2006,57 (2) :133--144.
-
7??? Advanced Bladder Cancer Meta analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta analysis[J], Lancet,2003,361 (9373) :1927 1934.
-
8Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer[J]. Eur Urol, 2005,48(2):202 -205.
-
9Winquist E, Kirchner T S, Segal R, et al. Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta analysis[J]. J Urol, 2004,171(2 Pt 1):561-569.
-
10International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial[J], Lancet,1999,354(9178):533-540.
同被引文献37
-
1王斌,周芳坚.浸润性膀胱癌化疗的现状[J].国外医学(泌尿系统分册),2004,24(6):753-755. 被引量:2
-
2姚欣,王华庆,马腾骧.膀胱癌系统化疗临床研究新进展[J].中华泌尿外科杂志,2004,25(12):860-863. 被引量:6
-
3梁朝朝 刘骋.浸润性膀胱尿路上皮癌的新辅助化疗.中华泌尿外科杂志,2007,.
-
4Sternberg CN,Pansadoro V,Calabro F,et al.Can patient selection for bladder preservation be based on response to chemotherapy[J] ?Cancer,2003,97(7):1644-1652.
-
5Von der Maase H,Hansen SW,Roberts JT,et al.Gemcitabine and cisplatin versus methotrexate,viblastine,doxorubcin,and cisplatin in advanced or metastatic bladder cancer:results of a large,randomized,multinational,multicenter,phase III study[J].J Clin Onco1,2000,18(17):3068-3077.
-
6马腾骧.膀胱癌的治疗[M]//泌尿、男性生殖系统肿瘤.北京:人民卫生出版社,2000:33-38.
-
7vonder Manse, Sengelov HL, Roberts JT, et al. Long - term survival results of a randomized trial comparing gemeitabine plus eisplatin, with methotrexate, vinblastine, doxombicin, plus cisplatin in patients with bladder cancer[J]. J Clin Oncol, 2005, 23(21 ) :4602 -4608.
-
8North S. Why consider neoadjuvant chemotherapy for muscle - invasive transitional cell carcinoma of the bladder[J]. Can Urol Assoc J, 2008, 2(3) :222 -224.
-
9Stemberg CN, de Mulder P, Schomagel JH, et al. Even year update of an EORTC phase Ⅲ trial of hish - dose intensity M - VAC chemothera- py and G - CSF versus classic M - VAC in advanced urothelial tract tumours[ J]. Eur J Cancer, 2006,42 ( 1 ) :50 -54.
-
10McLaushlin SJ, Shephard E, Wallen L, et al. Comparison of the clini- cal and pathologic staging in patients undergoing radical cystectomy for bladder cancer [ J]. Eur J Surg Oneol, 2007, 33 ( 1 ) :25 - 31.
引证文献4
-
1陶逸然,金讯波,王慕文,赵勇,于潇.吉西他滨联合顺铂新辅助化疗治疗肌层浸润性膀胱癌的临床疗效观察[J].泌尿外科杂志(电子版),2014,6(2):23-28. 被引量:12
-
2严旭阳,李东,杜广,袁平,方震,杨登科.吉西他滨联合奥沙利铂治疗浸润性和转移性尿路上皮癌的临床研究[J].中国肿瘤临床,2011,38(4):222-224. 被引量:10
-
3龚华,沈兵,谈明岳,范昱.顺铂为主的新辅助化疗方案治疗进展性膀胱癌的疗效分析[J].临床和实验医学杂志,2011,10(10):749-751. 被引量:7
-
4翟建坡,王建伟,王海东,满立波.肌层浸润性膀胱癌的新辅助化疗研究进展[J].肿瘤防治研究,2014,41(10):1129-1133. 被引量:6
二级引证文献35
-
1张勇杰,李新涛,赵旭鹏,董金凯,李学超,付成伟,麦海星,陈立军.新辅助化疗对肌层浸润性膀胱癌的肿瘤学效果及机器人手术的影响[J].微创泌尿外科杂志,2021(6):411-417.
-
2何苗,程宏文.替吉奥联合奥沙利铂治疗晚期结直肠癌的疗效观察[J].实用临床医药杂志,2011,15(17):110-112. 被引量:16
-
3徐子程,喻彬,须霆,杨尔炘,汪仪俊,邹青.吉西他滨联合顺铂的新辅助化疗治疗局部晚期膀胱移行细胞癌[J].中国肿瘤外科杂志,2012,4(5):268-270. 被引量:2
-
4宋文辉,马洪顺,杨世强,马庆彤,刘光明.低剂量吉西他滨联合奥沙利铂方案在晚期尿路上皮癌化疗中的疗效和安全性分析[J].中华泌尿外科杂志,2014,35(3):182-186. 被引量:6
-
5朱跃,蔡丽,毕雅莉,吴琼琼,王瑞娜.放射性粒子碘125插置组织间治疗晚期肿瘤的临床疗效[J].现代生物医学进展,2014,14(15):2929-2932. 被引量:5
-
6冯继,方军,方献英.吉西他滨联合奥沙利铂治疗尿路上皮肿瘤的疗效分析[J].中国现代药物应用,2014,8(12):169-170. 被引量:5
-
7刘敬涛,程永毅,孙羿,徐永刚,梁亮,王建忠.浸润性膀胱癌化疗的现状与进展[J].国际泌尿系统杂志,2014,34(4):569-574. 被引量:1
-
8李亚军,宋勇,宋琳,白鹏飞,高海东.低剂量吉西他滨联合奥沙利铂治疗浸润性尿路上皮癌的临床效果[J].中国肿瘤临床与康复,2014,21(9):1111-1113. 被引量:3
-
9吴庆成,李旭丹.培美曲塞单药全身化疗加局部放疗治疗老年晚期进展期泌尿系统肿瘤的疗效分析[J].中国继续医学教育,2015,7(2):157-158. 被引量:2
-
10伍静,赵云.新辅助化疗治疗局部晚期膀胱移行细胞癌12例临床护理[J].齐鲁护理杂志,2015,21(7):85-86. 被引量:1
-
1黄长海,王寅,辛永春,李晓东,林哲放,潘明君.肾肿瘤234例根治术后的临床研究[J].中国冶金工业医学杂志,2003,20(6):426-427.
-
2肖军,叶再生,魏晟宏,陈路川.进展期胃癌个体化扩大淋巴结清扫的临床探讨[J].消化肿瘤杂志(电子版),2015,7(3):130-132. 被引量:1
-
3封义兵,舒亦斌.乳腺癌改良根治术的改进对术后并发症的影响[J].浙江临床医学,2005,7(12):1262-1262. 被引量:1
-
4黄长海,王寅,辛永春,李晓东,林哲放,潘明君.肾肿瘤234例根治术后的临床研究[J].现代泌尿外科杂志,2004,9(2):78-79.
-
5金太欣,邵永胜,孟庆彬,肖新波,冯燕,李志刚.进展期胃下部癌第12p组淋巴结转移的相关因素分析[J].中华普通外科杂志,2015,30(6):486-488.
-
6陈凌武,梅骅.根治性膀胱切除与保存性功能[J].现代肿瘤医学,1995,3(3):135-137.
-
7林毅,张凌夫,许君武.48例腮腺良性肿瘤手术方式与术后并发症探讨[J].福建医药杂志,2006,28(5):97-98.
-
8闫河峰,张芳,王天喜,卢建路,冀强.膀胱癌腹腔镜根治性膀胱切除-尿流改道术的临床疗效[J].中国医药科学,2015,5(6):138-140. 被引量:5
-
9刘福杰.依胃癌的浸润深度及病变部位看根治术的合理性[J].中国实用医药,2011,6(19):80-81.
-
10曹晓锋,段建敏,魏希锋,康永明.膀胱尿路上皮癌中CD24、VEGF、MVD的表达及其临床意义[J].现代泌尿外科杂志,2009,14(2):118-120. 被引量:2